Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).
Michael Wang(St. Joseph Health System), Patrick M. Reagan(University of Rochester), Frederick L. Locke(Moffitt Cancer Center), Ioana Kloos, Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), John M. Timmerman(Sheba Medical Center), Krimo Bouabdallah(Centre Hospitalier Universitaire de Bordeaux), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Rhine R. Shen(Broad Institute), David B. Miklos(Stanford University), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Max S. Topp(Universitätsklinikum Würzburg), Xiang Fang, Houston Holmes(Texas Oncology), Peter A. McSweeney(Mesoblast (United States)), Ian W. Flinn(Tennessee Oncology), Weimin Peng(The University of Texas MD Anderson Cancer Center), Brian T. Hill(Cleveland Clinic)
Cited by 10
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k